scholarly article | Q13442814 |
P50 | author | Alan Knox | Q55030508 |
Miguel Camara | Q55294643 | ||
Paul Williams | Q55294657 | ||
Jane Lawrence-Dewar | Q59489232 | ||
Andrew Fogarty | Q59659803 | ||
Douglas L Forrester | Q81357991 | ||
Nigel Halliday | Q114444566 | ||
David Honeybourne | Q116792847 | ||
Joanna L Whitehouse | Q116792848 | ||
Alan R. Smyth | Q40855569 | ||
David A. Barrett | Q41452425 | ||
Edward Nash | Q42411763 | ||
P2093 | author name string | Andrew Clayton | |
Rebecca Simms | |||
Helen L Barr | |||
P2860 | cites work | Functional genetic analysis reveals a 2-Alkyl-4-quinolone signaling system in the human pathogen Burkholderia pseudomallei and related bacteria. | Q53591877 |
Regional variability of lung inflammation in cystic fibrosis. | Q54161497 | ||
Pseudomonas aeruginosa in chronic obstructive pulmonary disease. | Q54550554 | ||
Simultaneous quantitative profiling of N-acyl-l-homoserine lactone and 2-alkyl-4(1H)-quinolone families of quorum-sensing signaling molecules using LC-MS/MS | Q57920677 | ||
Standardisation of spirometry | Q29547365 | ||
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients | Q29615301 | ||
Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients | Q33559774 | ||
Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa | Q33982447 | ||
The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations | Q34437958 | ||
Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice | Q36095028 | ||
Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa | Q36520797 | ||
Toward implementation of quorum sensing autoinducers as biomarkers for infectious disease states | Q36704155 | ||
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection | Q37333170 | ||
Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules | Q37403126 | ||
Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections | Q37451009 | ||
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations | Q37591703 | ||
Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century | Q37780038 | ||
Defining a pulmonary exacerbation in cystic fibrosis | Q40685895 | ||
Comprehensive profiling of N-acylhomoserine lactones produced by Yersinia pseudotuberculosis using liquid chromatography coupled to hybrid quadrupole-linear ion trap mass spectrometry | Q41452345 | ||
Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology | Q42057512 | ||
Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. | Q42072983 | ||
The use of induced sputum to investigate airway inflammation | Q43043644 | ||
Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis--a pilot randomized controlled trial. | Q43122352 | ||
Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa | Q43189616 | ||
Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections | Q43593080 | ||
Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. | Q43910993 | ||
Sub-inhibitory concentrations of ceftazidime and tobramycin reduce the quorum sensing signals of Pseudomonas aeruginosa | Q46446718 | ||
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. | Q51711090 | ||
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. | Q51745373 | ||
Cooperation and conflict in quorum-sensing bacterial populations. | Q53557688 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Pseudomonas aeruginosa | Q31856 |
cystic fibrosis | Q178194 | ||
quorum sensing | Q905754 | ||
P304 | page(s) | 1046-1054 | |
P577 | publication date | 2015-05-28 | |
P1433 | published in | European Respiratory Journal | Q12257435 |
P1476 | title | Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis | |
P478 | volume | 46 |
Q110949013 | Alkyl-Quinolones derivatives as potential biomarkers for Pseudomonas aeruginosa infection chronicity in Cystic Fibrosis |
Q42630835 | Bactericidal Effect of Tomatidine-Tobramycin Combination against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Is Enhanced by Interspecific Small-Molecule Interactions |
Q57022025 | Characterization of the NQR complex, a bacterial proton pump with roles in autopoisoning resistance |
Q60949748 | Contribution of the Alkylquinolone Quorum-Sensing System to the Interaction of With Bronchial Epithelial Cells |
Q40580336 | Cystic Fibrosis Isolates of Pseudomonas aeruginosa Retain Iron-Regulated Antimicrobial Activity against Staphylococcus aureus through the Action of Multiple Alkylquinolones |
Q99411871 | Cytotoxic alkyl-quinolones mediate surface-induced virulence in Pseudomonas aeruginosa |
Q37631978 | Global impact of bronchiectasis and cystic fibrosis |
Q57789673 | Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the Quorum-Sensing System of Pseudomonas aeruginosa |
Q92857519 | In silico Analysis Reveals Distribution of Quorum Sensing Genes and Consistent Presence of LuxR Solos in the Pandoraea Species |
Q91900043 | Interference with Pseudomonas aeruginosa Quorum Sensing and Virulence by the Mycobacterial Pseudomonas Quinolone Signal Dioxygenase AqdC in Combination with the N-Acylhomoserine Lactone Lactonase QsdA |
Q57657193 | Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments |
Q100454961 | Micro-rheological properties of lung homogenates correlate with infection severity in a mouse model of Pseudomonas aeruginosa lung infection |
Q26776137 | Modulation of Host Biology by Pseudomonas aeruginosa Quorum Sensing Signal Molecules: Messengers or Traitors |
Q40610251 | Molecular Signature of Pseudomonas aeruginosa with Simultaneous Nanomolar Detection of Quorum Sensing Signaling Molecules at a Boron-Doped Diamond Electrode |
Q40288402 | Mycobacterium abscessus subsp. abscessus Is Capable of Degrading Pseudomonas aeruginosa Quinolone Signals |
Q36200942 | Natural products as mediators of disease. |
Q47120392 | PAMDB: a comprehensive Pseudomonas aeruginosa metabolome database. |
Q39265387 | Peptides as Quorum Sensing Molecules: Measurement Techniques and Obtained Levels In vitro and In vivo |
Q40166345 | Pseudomonas Quinolone Signal Induces Oxidative Stress and Inhibits Heme Oxygenase-1 Expression in Lung Epithelial Cells |
Q90251093 | Pseudomonas Quinolone Signal molecule PQS behaves like a B Class inhibitor at the IQ site of mitochondrial complex I |
Q92295532 | Pseudomonas aeruginosa Increases the Sensitivity of Biofilm-Grown Staphylococcus aureus to Membrane-Targeting Antiseptics and Antibiotics |
Q37643058 | Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence |
Q47119712 | Pseudomonas aeruginosa exoproducts determine antibiotic efficacy against Staphylococcus aureus. |
Q64252399 | Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens |
Q36194223 | Unravelling the Genome-Wide Contributions of Specific 2-Alkyl-4-Quinolones and PqsE to Quorum Sensing in Pseudomonas aeruginosa |
Q64063531 | Vertebrate odorant binding proteins as antimicrobial humoral components of innate immunity for pathogenic microorganisms |
Q40065639 | Weight gain during acute treatment of an initial pulmonary exacerbation is associated with a longer interval to the next exacerbation in adults with cystic fibrosis. |
Search more.